EGFR and non-small cell lung carcinoma: [76, 77] According to this study, Takashi Seto’el undertook an randomized, phase 2 trial (JO25567) [64, 78] to examine the efficacy and safety of erlotinib with or without bevacizumab as first-line therapy for patients with EGFR mutation NSCLC.